SCHEMBL5566873

SCHEMBL5566873

Cn1ccnc1C(c1ccc(Cl)cc1)c1ccc(N)cc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.38
KDM4E B2RXH2 2/20 0.37
LMNA P02545 3/20 0.35
KMT2A Q03164 2/20 0.35
TP53 P04637 2/20 0.35
ATM Q13315 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
VDR P11473 1/20 0.34
FFAR1 O14842 2/20 0.34
CYP19A1 P11511 2/20 0.34
MAPT P10636 2/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
PKM P14618 1/20 0.33
ALOX15 P16050 1/20 0.33
TSHR P16473 1/20 0.33
ALOX12 P18054 1/20 0.33
HSD17B10 Q99714 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL632748 0.73 KDM4E (0.45) L3MBTL1KDM4ELMNASMN1; SMN2VDR
SCHEMBL5007898 0.72 CYP3A4 (0.48) L3MBTL1KDM4ELMNAKMT2ATP53
SCHEMBL31629358 0.71 TGFBR1 (0.42) L3MBTL1KDM4ELMNAKMT2AFFAR1
SCHEMBL5565968 0.71 CYP19A1 (0.63) LMNAKMT2ATP53ATMSMN1; SMN2
SCHEMBL4905688 0.70 KDM4E (0.71) L3MBTL1KDM4ELMNAKMT2AMAPT
SCHEMBL31409219 0.69 TP53 (0.50) LMNAKMT2ATP53ATMSMN1; SMN2
SCHEMBL3904095 0.69 TP53 (0.50) LMNAKMT2ATP53ATMSMN1; SMN2
SCHEMBL31629390 0.68 TGFBR1 (0.40) L3MBTL1KDM4ELMNAKMT2AFFAR1
SCHEMBL6651894 0.67 KDM4E (0.71) L3MBTL1KDM4ELMNAKMT2ASMN1; SMN2
SCHEMBL5667003 0.67 CYP3A4 (0.42) KDM4ELMNAKMT2ATP53ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1000040-B1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2007-06-13 EP disclosed
US-20050090495-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs LACRAMPE JEAN FERNAND ARMAND (FR) 2005-04-28 US disclosed
US-6867207-B2 IL-5 inhibiting 6-azauracil derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2005-03-15 US disclosed
US-20040167333-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs LACRAMPE JEAN FERNAND ARMAND (FR) 2004-08-26 US disclosed
US-20020072603-A1 Novel IL-5 inhibiting 6-azauracil derivatives LACRAMPE JEAN FERNAND ARMAND (FR) 2002-06-13 US disclosed
EP-1000040-A1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2000-05-17 EP disclosed
WO-1999002505-A1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1999-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167333-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs IL6ST, CXCR5, ALOX5 L3MBTL1 3677/4885KDM4E 3074/4885LMNA 4455/4885
US-20050090495-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs CXCR5, HCAR3, IL6ST L3MBTL1 2350/4885KDM4E 3799/4885LMNA 4686/4885
US-20020072603-A1 Novel IL-5 inhibiting 6-azauracil derivatives IL6ST, ALOX5, IL5 L3MBTL1 3378/4885KDM4E 2126/4885LMNA 3842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.